Vaccination against hepatitis B in patients with inflammatory bowel disease: immune response and associated factors
e202202020
Keywords:
Hepatitis B virus (HBV), Inflammatory bowel disease, Vaccination, Hepatitis B/serologyAbstract
Background: Patients with Inflammatory Bowel Disease (IBD) are at increased risk of hepatitis B virus (HBV) infection as well as a lower response to vaccination. This study aimed to analyze the immune response after vaccination against HBV in patients diagnosed with IBD and its
associated factors.
Methods: A retrospective observational study was conducted on patients with IBD treated at the vaccination clinic for at-risk patients at the Complejo Hospitalario Universitario de Albacete during the period 2011-2018. Immune response after vaccination and associated factors were determined using logistic regression models.
Results: 231 patients were included. HBV Vaccination had an optimal immune response in 82.7% of the patients. The likelihood of response to vaccination increased in those diagnosed with ulcerative colitis (OR 2.90; 95% CI 1.11-7.61) and decreased with age (80% lower in those aged 40-55 years (OR 0.20; 95% CI 0.05-0.83) and 88% lower in those over 55 years of age (OR 0.12; 95% CI 0.03-0.53) compared to those under 40 years of age) and pharmacological immunosuppression (OR 0.20; 95% CI 0.58-0.71).
Conclusions: The decrease in the immunogenicity of the vaccine against hepatitis B in patients with IBD after the beginning of immunosuppressive treatment, as well as with age, make early vaccination a priority in this kind of patients.
Downloads
References
Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science. 2005 Mar;307(5717):1920–1925.
World Health Organization. Immunization, vaccines and biologicals-hepatitis B. 2012 [cited 2021 Mar 23]. Available from: https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/hepatitis#hepb
Hou JK, Velayos F, Terrault N, Mahadevan U. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis. 2010 Jun;16(6):925–932.
Lok ASF, McMahon BJ. Chronic hepatitis B. Vol. 45, Hepatology. 2007. 507–539 p.
Ministerio de Sanidad Consumo y Bienestar Social. Ponencia de Programa y Registro de Vacunaciones. 2018 [cited 2021 Dec 22]. Available from: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/programasDeVacunacion/riesgo/docs/VacGruposRiesgo_todas_las_edades.pdf
Chevaux J-B, Nani A, Oussalah A, Venard V, Bensenane M, Belle A et al. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis. 2010 Jun;16(6):916–924.
Van Aalst M, Garcia Garrido HM, Van Der Leun J, Meek B, Van Leeuwen EMM, Löwenberg M, et al. Immunogenicity of the Currently Recommended Pneumococcal Vaccination Schedule in Patients with Inflammatory Bowel Disease. Clin Infect Dis. 2020;70(4):595–604.
Jiang H-Y, Wang S-Y, Deng M, Li Y-C, Ling Z-X, Shao L et al. Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: A systematic review and meta-analysis. Vaccine. 2017 May;35(20):2633–2641.
Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011 Mar;33(6):619–633.
Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohns Colitis. 2010 Feb;4(1):28–62.
Carrera E, Manzano R, Garrido E. Efficacy of the vaccination in inflammatory bowel disease. World J Gastroenterol. 2013 Mar;19(9):1349–1353.
Pratt PKJ, David N, Weber HC, Little FF, Kourkoumpetis T, Patts GJ et al. Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients With Inflammatory Bowel Disease on Infliximab Therapy. Inflamm Bowel Dis. 2018 Jan;24(2):380–386.
Elkayam O. Safety and efficacy of vaccination against influenza in patients with rheumatoid arthritis. Clin Dev Immunol. 2006;13(2–4):349–351.
Sempere L, Almenta I, Barrenengoa J, Gutiérrez A, Villanueva CO, De-Madaria E et al. Factors predicting response to hepatitis B vaccination in patients with inflammatory bowel disease. Vaccine. 2013 Jun;31(30):3065–3071.
Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol. 2012 Oct;107(10):1460–1466.
Cunha I de S, Silva TC da, Malluta ÉF, Scolaro BL, Velho PS, Stall J. Seroconversion analysis after habitual hepatitis B vaccination scheme in patients with inflammatoty bowel diseases. Arq Gastroenterol. 2020;57(1):69–73.
Melmed GY, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006 Aug;101(8):1834–1840.
Brenner EJ, Jhaveri R, Kappelman MD, Gulati AS. Evaluating Hepatitis B Seroprotection and Revaccination for Children With Inflammatory Bowel Disease. Vol. 25, Inflammatory bowel diseases. England; 2019. p. e108.
Van Der Meeren O, Crasta P, Cheuvart B, De Ridder M. Characterization of an age-response relationship to GSK’s recombinant hepatitis B vaccine in healthy adults: An integrated analysis. Hum Vaccin Immunother. 2015;11(7):1726–1729.
Cossio-Gil Y, Martínez-Gómez X, Campins-Martí M, Rodrigo-Pendás JÁ, Borruel-Sainz N, Rodríguez-Frías F et al. Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination. J Gastroenterol Hepatol. 2015 Jan;30(1):92–98.
Bravo-Grande JL, Asunción Blanco-González M, de la Torre-Robles JM, Asmat-Inostrosa MP, Fernández-Escribano M, Villalobos IM et al. Vaccination adjuvated against hepatitis B in Spanish National Healthcare System (SNS) workers typed as non-responders to conventional vaccines. Vaccine. 2021;39(3):554–563.
Trevisan A, Frasson C, De Nuzzo D, Nicolli A, Scapellato ML. Significance of anti-HB levels below 10 IU/L after vaccination against hepatitis B in infancy or adolescence: an update in relation to sex. Hum Vaccin Immunother. 2020 Feb 1;16(2):460–464.
Trevisan A, Giuliani A, Scapellato ML, Anticoli S, Carsetti R, Zaffina S et al. Sex Disparity in Response to Hepatitis B Vaccine Related to the Age of Vaccination. Int J Environ Res Public Health. 2020 Jan 2;17(1):327.
European Medicines Agency. Fendrix. 2017 [cited 2021 Dec 22]. Disponible en: https://www.ema.europa.eu/en/medicines/human/EPAR/fendrix
García-Agudo R, Aoufi Rabih S, Araque Torres P, Dolores Fraga Fuentes M, Carlos Valenzuela Gámez J, Mancha Ramos J et al. Efficacy of a hepatitis B vaccination schedule with two cycles of four double doses of conventional vaccine and four doses of adjuvanted vaccine in chronic kidney disease patients evaluated for renal transplantation. Transplant Proc. 2012 Nov;44(9):2532–2534.
Tong NKC, Beran J, Kee SA, Miguel JL, Sánchez C, Bayas JM et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 2005 Nov;68(5):2298–2303.
Raven SFH, Hoebe CJPA, Vossen ACTM, Visser LG, Hautvast JLA, Roukens AHE et al. Serological response to three alternative series of hepatitis B revaccination (Fendrix, Twinrix, and HBVaxPro-40) in healthy non-responders: a multicentre, open-label, randomised, controlled, superiority trial. Lancet Infect Dis. 2020 Jan 1;20(1):92–101.
Machiels JD, Braam EE, van Bentum P, van Vugt M, De Vries-Sluijs TEMS, Schouten IWEM, et al. Vaccination with Fendrix of prior nonresponding patients with HIV has a high success rate. AIDS. 2019;33(3):503–507.
Fernández-Prada M, Rodríguez- Fonseca OD, Brandy- García AM, Alonso-Penanes P, Huerta-González I, Fernández-Noval F. Use of hepatitis B AS04C adjuvanted vaccine in HIV patients. 2018.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Sara Fernández Sánchez-Escalonilla, Óscar Esparcia Rodríguez, Ana López Cantos, José Miguel Cantero Escribano, Francisco Jesús Molina Cabrero, Ana Gómez-Juárez Sango, Jesús García Guerrero
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
